JPH01157382A - Purification of superoxide dismutase - Google Patents
Purification of superoxide dismutaseInfo
- Publication number
- JPH01157382A JPH01157382A JP62312179A JP31217987A JPH01157382A JP H01157382 A JPH01157382 A JP H01157382A JP 62312179 A JP62312179 A JP 62312179A JP 31217987 A JP31217987 A JP 31217987A JP H01157382 A JPH01157382 A JP H01157382A
- Authority
- JP
- Japan
- Prior art keywords
- sod
- solution
- acid
- treatment
- alkali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000019197 Superoxide Dismutase Human genes 0.000 title claims abstract description 5
- 108010012715 Superoxide dismutase Proteins 0.000 title claims abstract description 5
- 238000000746 purification Methods 0.000 title description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 108091005804 Peptidases Proteins 0.000 claims abstract description 8
- 239000004365 Protease Substances 0.000 claims abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 26
- 239000000356 contaminant Substances 0.000 claims description 23
- 238000011282 treatment Methods 0.000 abstract description 16
- 102000001554 Hemoglobins Human genes 0.000 abstract description 14
- 108010054147 Hemoglobins Proteins 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 7
- 239000003513 alkali Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 235000011121 sodium hydroxide Nutrition 0.000 abstract description 3
- 108090000284 Pepsin A Proteins 0.000 abstract description 2
- 102000057297 Pepsin A Human genes 0.000 abstract description 2
- 150000007522 mineralic acids Chemical class 0.000 abstract description 2
- 150000007524 organic acids Chemical class 0.000 abstract description 2
- 229940111202 pepsin Drugs 0.000 abstract description 2
- 108700033921 EC 3.4.23.20 Proteins 0.000 abstract 1
- 238000003307 slaughter Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 8
- 238000010306 acid treatment Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101100293599 Caenorhabditis elegans nas-5 gene Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 101150005399 sod2 gene Proteins 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
スーパーオキサイドジスムターゼ(以下SODと略す)
は細胞毒素として肋く活性酸素o2−を消去する反応を
触媒する酵素であり、炎症やリュウマチなどに対しての
薬理作用が知られている。最近では、食品中に生じた0
2″″の消去や生体内へのSODの補給を目的とする食
品として、さらには化粧品等への添加物としての利用も
検討されている。[Detailed description of the invention] [Industrial application field] Superoxide dismutase (hereinafter abbreviated as SOD)
is an enzyme that catalyzes a reaction that eliminates active oxygen O2-, which acts as a cytotoxin, and is known to have pharmacological effects on inflammation and rheumatism. Recently, 0
It is also being considered for use as a food for the purpose of eliminating SOD 2'' and replenishing SOD into the body, and also as an additive for cosmetics and the like.
このようなSODを、従来は安価で大量に入手可能な屠
畜血液等の動物血球から抽出しているため、ヘモグロビ
ン等の夾雑蛋白質の除去が必要である。Since such SOD has conventionally been extracted from animal blood cells such as slaughtered blood, which are inexpensive and available in large quantities, it is necessary to remove contaminant proteins such as hemoglobin.
本発明は、夾雑蛋白質を含むSOD溶液から夾雑蛋白質
を除去する方法に関し、詳しくは薬品。The present invention relates to a method for removing contaminant proteins from an SOD solution containing contaminant proteins, and specifically relates to a drug.
食品等として利用可能なSODを精製する方法に関する
ものである。This invention relates to a method for purifying SOD that can be used as food, etc.
[従来の技術]
SODを医薬品、特に注射薬等として用いる場合には、
免疫源性等の問題から高い比活性を有し、しかも極めて
純度の高いSODを抽出する必要がある。このようなS
ODを得る方法として、例えば赤血球溶血溶液に有機溶
媒あるいは重金属を添加し、室温あるいは50〜70℃
の範囲のSODの失活しない程度の熱処理を行い、大部
分の夾雑蛋白質を除去した後、ゲルー過、イオン交換等
の公知の精製方法を用いてSODを得る方法がある。[Prior art] When SOD is used as a medicine, especially an injection drug, etc.
Due to issues such as immunogenicity, it is necessary to extract SOD with high specific activity and extremely high purity. S like this
As a method for obtaining OD, for example, an organic solvent or heavy metal is added to a red blood cell hemolysate solution, and the mixture is heated at room temperature or 50 to 70°C.
There is a method of obtaining SOD using a known purification method such as gel filtration or ion exchange after heat treatment is performed to an extent that does not deactivate SOD in the range of 100 to 100% to remove most of the contaminant proteins.
しかしながら、この方法では、有機溶媒あるいは重金属
等の人体に有害な物質を用いることから、比教的大規模
な設備と精製後のSODからの有機溶媒あるいは重金属
等の分離及びその確認の工程を必要とする等の問題があ
る。However, since this method uses substances that are harmful to the human body, such as organic solvents or heavy metals, it requires large-scale equipment and a process to separate and confirm the organic solvents or heavy metals from SOD after purification. There are problems such as.
一方、SODを食品等として用いる場合には、医薬品と
して用いる場合に比べ、純度の面での制限は穏やかであ
る。例えば赤血球溶血溶液を材料としてSODを得る場
合には、赤色を呈するヘモグロビンが残留しない程度に
精製が行われていれば、一般的に問題はない、このよう
なSODを得る方法として、前述した様な方法を用いる
ことも可能であるが、この場合工程の複雑さや実施に要
する時間やコスト等の問題がある。他の方法としては従
来、赤血球溶血溶液等をSODが安定な50〜70°C
の温度範囲に加熱処理する方法かある。On the other hand, when SOD is used as a food or the like, there are less restrictions on purity than when it is used as a medicine. For example, when obtaining SOD using a red blood cell hemolysate as a material, there is generally no problem as long as the purification is carried out to the extent that red hemoglobin does not remain.As a method for obtaining such SOD, the method described above is used. It is also possible to use other methods, but in this case there are problems such as the complexity of the process and the time and cost required for implementation. Another method is to heat red blood cell hemolysate at a temperature of 50 to 70°C where the SOD is stable.
There is a method of heat treatment within the temperature range.
しかしながら、単独で熱処理を行うこの方法では、熱処
理で変性したヘモグロビン等の夾雑蛋白質の全てが沈澱
せず、従って、得られたSODが赤色を呈するため、そ
のままでは食品として使用しにぐいという問題点がある
。この方法で得られたSOD中の残留したヘモグロビン
等を除去し、食品として利用可能なSODを得るために
は、さらにゲルー過、イオン交換等の公知の精製技術を
行わなければならず、操作をできる限り簡略化して生産
コストを低下するという産業的な要求にそぐはない。However, this method of performing heat treatment alone does not precipitate all of the contaminant proteins such as hemoglobin that have been denatured by the heat treatment, and the resulting SOD has a red color, making it difficult to use as a food as it is. There is. In order to remove residual hemoglobin etc. from the SOD obtained by this method and obtain SOD that can be used as food, it is necessary to further perform known purification techniques such as gel filtration and ion exchange. It does not meet the industrial demands of reducing production costs by simplifying as much as possible.
以上の様な問題点を解決し、簡便な操作で食品として利
用可能なSODを精製でき、しかもゲル濾過、イオン交
換等の従来公知の技術を付加することで医薬品としても
利用可能なSODをvt製する方法について鋭意研究を
行った結果、SODは安定で夾雑蛋白質のみ変性させる
条件下で蛋白質分解酵素を作用させることで夾雑蛋白質
のみ分解可能なことを見い出し、本発明を完成させた。By solving the above problems, it is possible to purify SOD that can be used as food with simple operations, and by adding conventionally known techniques such as gel filtration and ion exchange, it is possible to produce SOD that can be used as a medicine. As a result of intensive research on the method for producing SOD, it was discovered that SOD is stable and that only contaminant proteins can be degraded by the action of proteolytic enzymes under conditions that denature only contaminant proteins, thereby completing the present invention.
すなわち、本発明は夾雑蛋白質を含むSOD溶液を酸性
及び/またはアルカリ性処理した後蛋白質分解で処理す
ることを特徴とするSODの精製法を提供するものであ
り、以下詳細に説明する。That is, the present invention provides a method for purifying SOD, which is characterized in that an SOD solution containing contaminant proteins is treated with acidity and/or alkalinity and then treated with proteolysis, and will be described in detail below.
[問題点を解決するための手段]
本発明は、例えば屠畜血液等から得た動物血球溶血溶液
、あるいはこれら溶血溶液中の大部分のヘモグロビンを
SODを失活させない様な、例えば熱処理、酸性処理、
アルカリ・1処理等で除去した動物血球溶血溶液由来の
夾雑蛋白質を含むSOD溶液等に提供されるものである
。これらSOD溶液に、まずSODは安定で夾雑蛋白質
のみを変性させる処理を行う。[Means for Solving the Problems] The present invention provides animal blood cell hemolysis solutions obtained, for example, from slaughtered blood, or most of the hemoglobin in these hemolysis solutions, by heat treatment, acid treatment, etc. that does not deactivate SOD. process,
It is applied to SOD solutions containing contaminant proteins derived from animal blood cell hemolysate solutions that have been removed by alkali-1 treatment or the like. These SOD solutions are first subjected to a treatment in which SOD is stable and only contaminant proteins are denatured.
夾雑蛋白質を変性させる手段としてはSODが変性せず
、夾雑蛋白質のみを変性させる酸処理。As a means of denaturing contaminant proteins, acid treatment is used to denature only the contaminant proteins without denaturing SOD.
アルカリ処理であれば制限なく使用可能であるが、本発
明では操作の簡略化のために人体に有害な物質を使用し
ない酸処理、アルカリ処理が好よしい。Although any alkaline treatment can be used without any restriction, in the present invention, acid treatment and alkaline treatment that do not use substances harmful to the human body are preferable in order to simplify the operation.
例えば、p)12〜6の範囲における塩酸、リン酸。For example, p) hydrochloric acid, phosphoric acid in the range of 12-6.
#酸、炭酸、乳酸、クエン酸等の食品衛生法で制限をう
けない有機、無機酸による酸処理、または前述の酸の塩
や化成ソーダ、アンモニア等によるP H9〜12の範
囲におけるアルカリ処理では、SODの変性が観察され
ず、しかも例えば動物血球溶血溶液由来のSOD溶液中
に存在するヘモグロビン等の変性を引き起こすため本発
明で好ましく採用される0食品衛生法で制限を受けない
酸。#Acid treatment with organic or inorganic acids that are not restricted by the Food Sanitation Act, such as acid, carbonic acid, lactic acid, citric acid, or alkaline treatment in the pH range of 9 to 12 with salts of the aforementioned acids, chemical soda, ammonia, etc. , an acid which is not subject to restrictions under the Food Sanitation Law and is preferably employed in the present invention because it does not cause denaturation of SOD and causes denaturation of hemoglobin, etc. present in the SOD solution derived from, for example, an animal blood cell hemolysate solution.
アルカリ性物質としては、食品中の食品添加物分析法(
講談社)等を参照すると良い。As alkaline substances, food additive analysis method (
Please refer to Kodansha) etc.
これらの処理は単独で用いることによってもヘモグロビ
ン等の夾雑蛋白質を編成させるには十分であるが、他の
変性しにくい夾雑蛋白質か存在する場合にはこのような
処理を繰り返し行うことも可能であり、さらには、例え
ば酸性処理後、後に記述する様な酵素を添加して変性し
た夾雑蛋白質を分解し、さらにアルカリ処理をして、酵
素を添加しても良い。These treatments alone are sufficient to organize contaminant proteins such as hemoglobin, but if other contaminant proteins that are difficult to denature are present, it is also possible to repeat these treatments. Furthermore, for example, after acid treatment, an enzyme as described later may be added to decompose the denatured contaminant protein, followed by alkaline treatment, and then the enzyme may be added.
以上の様な処理は、SODが安定な室温程度で行えば良
いが、後に記述する使用する酵素の最適温度等を考慮し
て30〜70℃の条件下で行っても良い。The above-mentioned treatment may be carried out at about room temperature where the SOD is stable, but it may also be carried out at a temperature of 30 to 70°C in consideration of the optimum temperature of the enzyme used, which will be described later.
蛋白質分解酵素としては、夾雑蛋白質をS OD(通常
2量体として存在し、その分子量は3万2千である。)
と限外濾過透析等の一般的方法により分離可能な低分子
ペプチドにまで分解しうるちのであれは制限はないが、
具体的にはペプシン。As a proteolytic enzyme, SOD (usually exists as a dimer and has a molecular weight of 32,000) contaminant proteins.
There is no restriction as long as it can be broken down into low molecular weight peptides that can be separated by general methods such as ultrafiltration and dialysis.
Specifically, pepsin.
ベニシロペプシン、カベグジン、スゲチリシン。benicilopepsin, cabegudin, sugetilisin.
キモトリプシン等の基質特異性の低いアスパラティック
プロテアーゼが好ましい。酵素の添加量は実施者が用い
る酵素の活性等の諸条件によって経験的に決定すること
が必要であるが、本発明者の経験によると、溶血溶液中
の総蛋白質の1/10〜1/1000が適当であった。Asparatic proteases with low substrate specificity, such as chymotrypsin, are preferred. The amount of enzyme added needs to be determined empirically depending on the conditions such as the activity of the enzyme used by the practitioner, but according to the experience of the present inventors, the amount of added enzyme is 1/10 to 1/1 of the total protein in the hemolytic solution. 1000 was appropriate.
酵素は一般的に、その活性を有効に発揮し得る最適pH
,ilt適温度をもつことが知られている。Enzymes generally have an optimum pH at which they can effectively exert their activity.
, is known to have a suitable temperature.
このため変性処理後の溶血溶液は蛋白質分解酵素の添加
に先立ち、使用する酵素にあわせてp Hや温度を調整
するか、あるいは溶血溶液の状態にあわせて酵素を選択
的に採用すれば良い。例えは酸処理により変性させた場
合は酸性領域に最適pHを有する酵素を、アルカリ処理
による場合はアルカリ性に最適p Hを有する酵素を使
用する。For this reason, the pH and temperature of the hemolytic solution after denaturation treatment may be adjusted prior to the addition of proteolytic enzymes depending on the enzyme used, or the enzyme may be selectively employed depending on the state of the hemolytic solution. For example, when denaturation is carried out by acid treatment, an enzyme having an optimum pH in the acidic region is used, and in case of alkaline treatment, an enzyme having an optimum pH in the alkaline region is used.
また、必要によっては酵素の最適温度に合わせて70’
C以下の温度範囲に加熱することもできる。Also, if necessary, adjust the temperature to 70' to match the optimum temperature of the enzyme.
Heating can also be carried out to a temperature range below 50°C.
以上の操作により該溶液中の夾雑蛋白質はペプチドに分
解され、その一部は不溶化するので遠心分離や濾過法等
の公知の技術により除去し、また溶液中に残存する低分
子のペプチドは限外濾過や透析により除去することがで
きる。Through the above operations, the contaminant proteins in the solution are decomposed into peptides, some of which become insolubilized, so they are removed by known techniques such as centrifugation and filtration, and low-molecular-weight peptides remaining in the solution are It can be removed by filtration or dialysis.
[発明の効果]
本発明により、SOD溶液中の夾雑蛋白質の大部分を除
去することができる。特に、動物赤血球溶血溶液由来の
SOD溶液を本発明を用いてvj製した場合には、精製
したSODを食品として利用する場合の障害となるヘモ
グロビンの残留は認められない。本発明で動物赤血球溶
血溶液を原料として得られたSODは、原料に対して5
〜20倍の比活性を有しており、食品さらには医薬品等
に利用することができるものである。[Effects of the Invention] According to the present invention, most of the contaminant proteins in the SOD solution can be removed. In particular, when an SOD solution derived from an animal red blood cell hemolysate solution is produced using the present invention, no residual hemoglobin is observed, which would be an obstacle when using purified SOD as a food. In the present invention, the SOD obtained using animal red blood cell hemolysis solution as a raw material is 5% relative to the raw material.
It has a specific activity ~20 times higher, and can be used in foods and even medicines.
本発明で得られるSODは、夾雑蛋白質を分解するため
使用する酵素等を含んでいるため、そのままでは医薬品
、特に注射薬等としては使用できないが、このSODを
材料として、ゲルア過、イオン交換等の従来公知の精製
方法により、極めて容易に高純度SODを得ることがで
きる。この場合、本発明では人体に有害な物質の使用を
必要としないため、従来の方法に比べ必要な設備、工程
等を簡略化することかできる。また、SODを食品とし
て使用する場合にも、本発明では人体に有害な物質の使
用を必要としないため、簡単な操作により、即時に食品
として使用可能なSODを得ることができる。Since the SOD obtained by the present invention contains enzymes used to decompose contaminant proteins, it cannot be used as a medicine as it is, especially as an injection drug. However, it can be used as a material for gel filtration, ion exchange, etc. High purity SOD can be obtained extremely easily by the conventionally known purification method. In this case, since the present invention does not require the use of substances harmful to the human body, the necessary equipment, processes, etc. can be simplified compared to conventional methods. Furthermore, even when using SOD as food, the present invention does not require the use of substances harmful to the human body, so SOD that can be used as food can be obtained immediately by simple operations.
従来の熱処理によるSODの精製法においても、食品等
に利用可能なSODを得ることは可能であるが、本発明
では酵素処理により夾雑蛋白質をペプチドに分解するた
め、遠心分疏、濾過、限外濾過法等の簡便、迅速に大量
のSODと、このペプチドを分離する方法を採用するこ
とが可能であるので、分離の際、ゲル濾過、イオン交換
法等の方法でSODと変性夾雑蛋白を分離する必要のあ
る該方法よりも収率、操作性を上げ生産コスト等を低減
することが可能である。Although it is possible to obtain SOD that can be used in foods, etc. using the conventional heat treatment method for purifying SOD, the present invention uses enzyme treatment to decompose contaminant proteins into peptides, so centrifugal separation, filtration, ultraviolet filtration, etc. Since it is possible to use a simple and quick method such as filtration to separate large amounts of SOD from this peptide, it is possible to separate SOD and denatured contaminant proteins using methods such as gel filtration and ion exchange. It is possible to increase the yield and operability and reduce production costs, etc., compared to the method that requires the following steps.
以下本発明をさらに詳細に説明するために、実施例を示
すが、本発明はこれら実施例に限定されるものではない
。EXAMPLES Below, Examples will be shown to explain the present invention in more detail, but the present invention is not limited to these Examples.
[実施例]
実施例1
水で5@に希釈してブタ赤血球を溶血させ1ON苛性ソ
ーダを滴下してpH10,5に調整し、室温で1時間放
置後12N塩酸を滴下してpH3,5に調整し、30分
後、ION苛性ソーダで中和することによってヘモグロ
ビンを変性させ沈澱除去してSOD溶液(SOD活性6
0 U / [!I+、比活性18U/■)400a+
Iを得な。この溶液に12N塩酸を滴下してpH5,0
に調整し、45℃に保温してモルシン(盛運製薬社製>
90■を加え、撹拌しつつ一晩放置しな。[Example] Example 1 Pig red blood cells were diluted to 5@ with water to hemolyze them, 1ON caustic soda was added dropwise to adjust the pH to 10.5, and after being left at room temperature for 1 hour, 12N hydrochloric acid was added dropwise to adjust the pH to 3.5. After 30 minutes, the hemoglobin is denatured by neutralization with ION caustic soda, the precipitate is removed, and an SOD solution (SOD activity 6
0 U / [! I+, specific activity 18U/■) 400a+
Get I. Add 12N hydrochloric acid dropwise to this solution to pH 5.0.
After adjusting the temperature to
Add 90 quarts of water and leave it overnight while stirring.
この操作で生じた不溶物をケイソウ土沢過により除去し
、さらに得られた上清を純粋に対して透析して得られた
SOD溶液についてSOD活性および蛋白濃度を測定し
なところ、SOD活性68U / ml、SOD比活性
は340U/ragであり、純度は約20倍に上昇しな
。The insoluble matter generated in this operation was removed by diatomaceous filtration, and the resulting supernatant was further dialyzed against pure SOD solution. When the SOD activity and protein concentration were measured, the SOD activity was 68 U / ml, SOD specific activity was 340 U/rag, and purity increased approximately 20 times.
この溶液はヘモグロビンに由来する赤色を呈していなか
った。This solution did not exhibit the red color derived from hemoglobin.
なお、SOD活性はJ、M、McCord&I。Note that SOD activity was determined by J, M, McCord & I.
Fr i dou i ch (J、B t o 1.
Chem。Fri dou ich (J, B t o 1.
Chem.
244.6049 (1969年))の方法で測定し、
蛋白濃度はBioRad社製Prate i nAs5
ay Kitで測定した。244.6049 (1969)),
Protein concentration was Prate i nAs5 manufactured by BioRad.
Measured with ay Kit.
図1は、実施例1で得られたブタ赤血球溶血溶液をアル
カリ処理、酸処理してヘモグロビン等の火難蛋白質の大
部分を除去した原料であるSOD溶潅■及び得られた精
製SOD溶液■の吸収スペクトル図である。
原料としたSOD溶液には主な夾雑蛋白質であるヘモグ
ロビンに起因し赤色の原因である40゜n Ill付近
の強い吸収が存在するが、本発明により得られたSOD
溶液においてはこの吸収が存在しない。これはSOD溶
液中のヘモグロビンが除去されていることを示すもので
あり、同時にSOD溶液が無色であることを示すもので
ある。
測定に際しては、2つのSOD溶液の280nmの吸光
度がほぼ一致するように調整したくこの吸収は蛋白質中
のチロシンおよびトリプトファン残基に由来し、蛋白質
濃度をしる目安になる)。
なお、280nmでの吸光度は、■:
0.309.■:0.287であった。Figure 1 shows SOD solution (1), which is a raw material obtained by treating the pig red blood cell hemolysis solution obtained in Example 1 with alkali treatment and acid treatment to remove most of the fire-retardant proteins such as hemoglobin, and the purified SOD solution (2). It is an absorption spectrum diagram. The SOD solution used as a raw material has strong absorption near 40°n Ill, which is caused by hemoglobin, which is the main contaminant protein, and is the cause of the red color.
In solution this absorption is absent. This indicates that hemoglobin in the SOD solution has been removed, and at the same time indicates that the SOD solution is colorless. During the measurement, the absorbance at 280 nm of the two SOD solutions should be adjusted so that they are almost the same (this absorption originates from tyrosine and tryptophan residues in proteins and is a measure of protein concentration). In addition, the absorbance at 280 nm is ■: 0.309. ■: 0.287.
Claims (1)
ーゼ溶液を酸性及び/またはアルカリ性処理した後、蛋
白質分解酵素で処理することを特徴とするスーパーオキ
サイドジスムターゼの精製法。(1) A method for purifying superoxide dismutase, which comprises acidifying and/or alkaline treating a superoxide dismutase solution containing contaminant proteins and then treating it with a protease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62312179A JPH01157382A (en) | 1987-12-11 | 1987-12-11 | Purification of superoxide dismutase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62312179A JPH01157382A (en) | 1987-12-11 | 1987-12-11 | Purification of superoxide dismutase |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01157382A true JPH01157382A (en) | 1989-06-20 |
Family
ID=18026171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62312179A Pending JPH01157382A (en) | 1987-12-11 | 1987-12-11 | Purification of superoxide dismutase |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01157382A (en) |
-
1987
- 1987-12-11 JP JP62312179A patent/JPH01157382A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3195937B2 (en) | Method for obtaining amylase inhibitor | |
JPS5858061B2 (en) | Method for producing purified protein hydrolyzate | |
JPS59137417A (en) | Preparation of colonization stimulation factor and kallikrein originated from human urine | |
CN104593457A (en) | Micro-molecule polypeptide with function of removing free radicals | |
SE451539B (en) | HOME IRON-ENRICHED AMINO ACID PREPARATION MADE BY HOME PROTEINS AND PROCEDURE FOR ITS PREPARATION | |
JP3139563B2 (en) | Method for producing rice bran protein-derived peptide | |
EP2503333B1 (en) | Electrophoretic analysis method | |
KR20100011850A (en) | A method for preparing a extract of pig placenta | |
JPH02265441A (en) | Method for selective enzymic hydrolysis of beta-lactoglobulin in cow's milk whey protein | |
JPH01157382A (en) | Purification of superoxide dismutase | |
CN110810852A (en) | Preparation method of earthworm freeze-dried powder for regulating cardiovascular function | |
CN106831938B (en) | method for preparing donkey-hide gelatin small-molecule low-peptide | |
CN114573682A (en) | Elastin peptide and preparation method thereof | |
JPH1052267A (en) | Activation of prothrombin and production of thrombin based on activation thereof | |
JP2560363B2 (en) | Method for purifying chitin or chitosan | |
Piot et al. | Preparation of decolorized peptides from slaughter-house blood | |
CN111018867A (en) | Method for quickly extracting heme from hemoglobin | |
JP2681650B2 (en) | Method for producing casein peptide | |
JPS6159610B2 (en) | ||
JP3437738B2 (en) | Method for producing protein hydrolyzate with reduced odor | |
CN1041170C (en) | Bromelin decrustation preparation and its preparing method | |
JPS61171431A (en) | Amylase-inhibiting substance and preparation thereof | |
TWI617315B (en) | Bass extract with an effect on the stimulation and maintenance of bone | |
JP3682994B2 (en) | Process for producing peptide mixtures with low phenylalanine content | |
JPH11225686A (en) | Casein hydrolysate and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041018 |
|
R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081022 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091022 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 6 Free format text: PAYMENT UNTIL: 20101022 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 7 Free format text: PAYMENT UNTIL: 20111022 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 7 Free format text: PAYMENT UNTIL: 20111022 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 8 Free format text: PAYMENT UNTIL: 20121022 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121022 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20131022 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |